title: Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes.
abstract: OBJECTIVE
  Individuals with type 2 diabetes (T2DM) are at increased risk of cardiovascular disease, including heart failure (HF). In patients with T2DM elevated serum concentrations of the N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP) correlate with cardiovascular morbidity and mortality. We aimed to identify predictors of increased serum NT-proBNP levels in patients with T2DM.
  
  
  METHODS
  The study included 185 patients with T2DM treated with either oral antidiabetic agents (49.7%) or insulin (17.8%), or both (32.5%). We divided the patients into two groups: with high (>200 pg/mL) and low (≤200 pg/mL) NT-proBNP concentrations.
  
  
  RESULTS
  We found differences between the patients with high and low NT-proBNP levels including age, prevalence of dyslipidemia and HF, history of previous myocardial infarction (MI), heart rate, hemoglobin level, platelet count, creatinine, urea and uric acid concentrations, use of beta-blockers, loop diuretics, metformin and insulin. In a multivariate analysis metformin was a negative predictor of increased NT-proBNP concentration. Age, history of HF and decreased estimated glomerular filtration rate (eGFR) were positive predictors. We found no correlation between NT-proBNP serum concentration and insulin treatment or history of coronary artery disease or MI.
  
  
  CONCLUSIONS
  Metformin correlates with lower concentrations of NT-proBNP in patients with T2DM.
authors: M
authors: M
authors: Rosiak
authors: M
authors: M
authors: Postula
authors: A
authors: A
authors: Kaplon-Cieslicka
authors: E
authors: E
authors: Trzepla
authors: A
authors: A
authors: Czlonkowski
authors: K J
authors: KJ
authors: Filipiak
authors: G
authors: G
authors: Opolski
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D050197:Atherosclerosis / Q000188:drug therapy / Q000401:mortality; D001645:Biguanides / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000401:mortality*; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000401:mortality; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D008687:Metformin / Q000627:therapeutic use*; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D010446:Peptide Fragments / Q000097:blood*; D011237:Predictive Value of Tests; D015995:Prevalence; D012307:Risk Factors
chemical_list: D000319:Adrenergic beta-Antagonists; D001645:Biguanides; D004232:Diuretics; D007004:Hypoglycemic Agents; D007328:Insulin; D010446:Peptide Fragments; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D008687:Metformin